losartan carboxylic acid

structure given in first source

Also Known As:

1H-imidazole-5-carboxylic acid, 2-butyl-4-chloro-1-((2'-(2H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-; 2-n-butyl-4-chloro-1-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methylll)imidazole-5-carboxylic acid; E-3174; EXP 3174; EXP-3174; EXP3174

Networked: 31 relevant articles (3 outcomes, 7 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Chabielska, E: 2 articles (06/2019 - 07/2001)
2.	Abadir, Peter M: 1 article (05/2022)
3.	Anders, Nicole M: 1 article (05/2022)
4.	Bichara, Marcela-Dávalos: 1 article (05/2022)
5.	Buta, Brian: 1 article (05/2022)
6.	Carey, Robert M: 1 article (05/2022)
7.	Ferrucci, Luigi: 1 article (05/2022)
8.	Gabrawy, Mariann M: 1 article (05/2022)
9.	Khadeer, Mohammed: 1 article (05/2022)
10.	Kwak, Min-Ji: 1 article (05/2022)

Related Diseases

1.	Hypertension (High Blood Pressure) 05/01/1995 - "These results suggested that either ANG II-hypertension does not involve brain AT1 receptors, or that i.c.v. EXP 3174 may not gain access to brain sites at which circulating ANG II acts to produce hypertension. " 05/01/1995 - "Although the dose of EXP 3174 used in preliminary experiments was shown to block the responses to i.c.v. ANG II this treatment did not lower MAP in chronic ANG II-hypertension. " 01/01/2019 - "Exp3174 is an active metabolite of losartan for the treatment of hypertension. " 01/01/2022 - "Conclusion: In conclusion, SMI improved the antihypertensive efficacy of LOS in the L-NAME-induced hypertension rat model by increasing the concentration of LOS, while leaving the concentration of EXP3174 intact. " 01/01/2019 - "Carboxylesterase 2 and Intestine Transporters Contribute to the Low Bioavailability of Allisartan, a Prodrug of Exp3174 for Hypertension Treatment in Humans."
2.	Myocardial Ischemia (Ischemic Heart Diseases) 09/01/1999 - "The antiarrhythmic efficacy of EXP3174 may be due to an attenuation of deleterious effects of local cardiac AII formed during acute myocardial ischemia or, alternatively, a non-AII-related activity specific to EXP3174. " 10/01/2007 - "The purpose of this study was to determine whether angiotensin AT1 receptor blockade by losartan or its active metabolite EXP3174 protects against myocardial ischemia-reperfusion injury in mice and whether this protection is mediated by the kallikrein kinin system. "
3.	Paralysis (Palsy) 12/01/2003 - "Losartan, its active metabolite EXP3174, and valsartan given intraperitoneally 1 hour before the thrombotic challenge (in doses of 3, 10, or 30 mg/kg) protected mice from death or hind-limb paralysis in response to intravenous injection of a mixture of collagen and epinephrine; losartan was effective in all doses used, whereas EXP3174 and valsartan reduced mortality only in the two higher doses. "
4.	Heart Failure 01/01/2001 - "The aim of this study was to evaluate the acute effects of E-3174, a human active metabolite of the AT1 receptor antagonist, losartan, on hemodynamic functions in dogs with severe heart failure (HF). " 04/01/1999 - "EXP 3174 (0.1 mg/kg, i.v.) or enalaprilat (1 mg/kg, i.v.) were administered in conscious dogs with heart failure induced by right ventricular pacing (250 beats/min, 3 weeks). " 01/01/2001 - "Acute effects of E-3174, a human active metabolite of losartan, on the cardiovascular system in tachycardia-induced canine heart failure." 04/01/1999 - "This study was designed to assess the influence of the activation status of the renin angiotensin system (RAS) on the hemodynamic effects of EXP 3174 (an angiotensin AT1 receptor antagonist) and enalaprilat (an angiotensin converting enzyme inhibitor) in tachycardia-induced heart failure. "
5.	Reperfusion Injury 10/01/2007 - "The purpose of this study was to determine whether angiotensin AT1 receptor blockade by losartan or its active metabolite EXP3174 protects against myocardial ischemia-reperfusion injury in mice and whether this protection is mediated by the kallikrein kinin system. " 11/01/1993 - "1. In order to determine whether the renin-angiotensin system is involved in myocardial ischaemia-reperfusion injury, we investigated and compared the effects on infarct size of two different drugs which interfere with this system, i.e., an angiotensin II (AT1) antagonist, EXP3174, and an angiotensin I-converting enzyme inhibitor (ACEI), enalaprilat in a canine model of ischaemia-reperfusion. "

Related Drugs and Biologics

1.	Losartan (Cozaar)
2.	Antihypertensive Agents (Antihypertensives)
3.	Valsartan (Vals)
4.	NG-Nitroarginine Methyl Ester (L-NAME)
5.	Epinephrine (Adrenaline)
6.	Collagen
7.	Type 1 Angiotensin Receptor
8.	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
9.	Enalaprilat (Vasotec)
10.	2- butyl- 4- chloro- 1- ((2'- (1H- tetrazol- 5- yl)(1,1'- biphenyl)- 4- yl)methyl)- 1H- imidazole- 5- carboxaldehyde

Related Therapies and Procedures

1.	Intravenous Injections
2.	Oral Administration